To advance SeaBeLife's dual-pathway strategy targeting retinal degeneration by appointing Professor Eric Souied to its scientific committee, which focuses on innovative treatment mechanisms.
Key Findings:
Souied has extensive expertise in AMD, having authored over 650 scientific publications.
He identified the first genetic polymorphism associated with AMD in 1998.
SeaBeLife's lead candidate, SBL03, has shown preclinical efficacy in geographic atrophy (GA), which is projected to affect 10 million people by 2040.
Interpretation:
Souied's appointment strengthens SeaBeLife's scientific foundation and enhances its focus on innovative treatment strategies for retinal degeneration.
Limitations:
Limited treatment options for GA in Europe highlight the urgent need for effective therapies as cases are projected to rise significantly.
Conclusion:
The collaboration aims to develop a disease-modifying approach to retinal degeneration, focusing on innovative strategies that target underlying mechanisms rather than just alleviating symptoms.
Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.
